Literature Review on the Immunogenicity of Herpes Zoster Vaccines

Literature Review on the Immunogenicity of Herpes Zoster Vaccines Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines. 2019-04-25 Public Health Agency of Canada open-ouvert@tbs-sct.gc.ca Health and SafetyHerpeszosteracuteviralinfectionreactivationvaricella-zoster virusVZVLZVliveattenuatedvaccinezosterCanadasubunitrecombinant zoster vaccineRZVShingrixCanada2017zoster vaccineimmunogenicitylivesubunit vaccines Literature Review on the Immunogenicity of Herpes Zoster VaccinesHTML https://www.canada.ca/en/public-health/services/publications/healthy-living/literature-review-immunogenicity-herpes-zoster-vaccines.html Literature Review on the Immunogenicity of Herpes Zoster VaccinesHTML https://www.canada.ca/fr/sante-publique/services/publications/vie-saine/revue-litterature-immunogenicite-vaccins-contre-zona.html

Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines.

Data and Resources

Similar records